Nicox reported that the Mississippi Phase IIb study assessing NCX-4251 against placebo in patients with acute exacerbations of blepharitis did not meet its primary or secondary efficacy endpoints. Although we reduce our NCX-4251 probability of success and push out its potential launch timelines, this does not substantially affect our valuation of the company, as we continue to view the primary driver (c 80% of our rNPV valuation) as the NCX-470 programme in glaucoma. Top-line data from Mont Blan ....
24 Sep 2021
Nicox - NCX-4251 setback sharpens focus on NCX-470
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Nicox - NCX-4251 setback sharpens focus on NCX-470
- Published:
24 Sep 2021 -
Author:
Pooya Hemami -
Pages:
5
Nicox reported that the Mississippi Phase IIb study assessing NCX-4251 against placebo in patients with acute exacerbations of blepharitis did not meet its primary or secondary efficacy endpoints. Although we reduce our NCX-4251 probability of success and push out its potential launch timelines, this does not substantially affect our valuation of the company, as we continue to view the primary driver (c 80% of our rNPV valuation) as the NCX-470 programme in glaucoma. Top-line data from Mont Blan ....